Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $10.9 million.

  • Janux Therapeutics' Non Operating Income rose 4053.71% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.4 million, marking a year-over-year increase of 6673.09%. This contributed to the annual value of $29.9 million for FY2024, which is 10327.52% up from last year.
  • Latest data reveals that Janux Therapeutics reported Non Operating Income of $10.9 million as of Q3 2025, which was up 4053.71% from $11.3 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Non Operating Income ranged from a high of $11.4 million in Q1 2025 and a low of $46000.0 during Q2 2021
  • Its 5-year average for Non Operating Income is $4.6 million, with a median of $3.7 million in 2023.
  • As far as peak fluctuations go, Janux Therapeutics' Non Operating Income surged by 287432.43% in 2022, and later soared by 4053.71% in 2025.
  • Janux Therapeutics' Non Operating Income (Quarter) stood at $74000.0 in 2021, then surged by 2874.32% to $2.2 million in 2022, then soared by 98.96% to $4.4 million in 2023, then soared by 101.1% to $8.8 million in 2024, then rose by 24.21% to $10.9 million in 2025.
  • Its Non Operating Income stands at $10.9 million for Q3 2025, versus $11.3 million for Q2 2025 and $11.4 million for Q1 2025.